Jay Bernstein
Family Medicine · Phoenix, AZNPI 1649233396
Payments from drug & device makers
Across 302 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$362
- Boehringer Ingelheim$361
- Novo Nordisk$300
- Takeda Pharmaceuticals U.S.A., Inc.$294
- AstraZeneca$288
- plus $3K from 42 others
What the payments were for
- Food & beverage$5,595100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UNID_PASS$136
- UBRELVY$123
- Tresiba$120
- XIFAXAN$110
- TRELEGY ELLIPTA$108
How this compares
$5,595 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 51 | $61,447 |
| OzempicSemaglutide | 23 | $44,599 |
| RybelsusSemaglutide | 15 | $41,875 |
| FarxigaDapagliflozin Propanediol | 22 | $35,655 |
| JardianceEmpagliflozin | 28 | $35,353 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 33 | $35,296 |
| TrulicityDulaglutide | 17 | $33,950 |
| MyrbetriqMirabegron | 20 | $22,426 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $12,229 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $9,618 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $4,913 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 21 | $4,397 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 50 | $3,449 |
| Atorvastatin Calcium | 338 | $3,287 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $3,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $300 | $86,47438 claims |
| PfizerEliquis | $220 | $61,44751 claims |
| AstraZenecaFarxiga, Symbicort | $288 | $45,27238 claims |
| Boehringer IngelheimJardiance | $361 | $35,35328 claims |
| Lilly USA, LLCTrulicity | $155 | $33,95017 claims |
| Astellas Pharma US IncMyrbetriq | $232 | $22,42620 claims |
| GSKTrelegy Ellipta, Shingrix | $181 | $16,62634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Phoenix
- Brock MerrittPhoenix$8.4M
- Douglas CunninghamPhoenix$4.9M
- Jeffrey ZacherPhoenix$2M
- Trisha TavaresPhoenix$1.6M
- David FrancykPhoenix$1.3M
- James BeachPhoenix$1.2M
- Peter LevinsPhoenix$971K
- Elysa ShawPhoenix$774K
- Mitchell EdelsteinPhoenix$741K
- Brian DedinskyPhoenix$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.